Combination treatment with anti-CTLA4 led to a significant decrease in tumor growth in the tested subcutaneous model compared to each drug alone;dual checkpoint blockade (anti-PD1 and anti-CTLA4) combination with PT2399 led to decreased tumor growth and enhanced survival in the orthotopic model (combined with anti-pd1). The gene discussed is CTLA4; the disease is neoplasm.